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Summary Background The combination of bevacizumab
(B) and erlotinib (E) has shown promising clinical outcomes
as the first-line treatment of advanced HCC patients. We
aimed to evaluate the efficacy and safety of using combina-
tion of B+E in treating advanced HCC patients who had
failed prior sorafenib treatment. Methods Eligible advanced
HCC patients with documented radiological evidence of
disease progression with sorafenib treatment were recruited.
All patients received bevacizumab(B) at 10 mg/kg every
2 weeks with erlotinib(E) at 150 mg daily for a maximum
of 6 cycles. Response assessments using both RECIST and
modified RECIST criteria were performed after every
6 weeks. The primary endpoint was clinical benefit (CB)
rate and a Simon two-stage design was employed.
Results The trial was halted in the first stage according
to the pre-set statistical criteria with 10 patients recruited.
The median age was 47 years (range, 28–61) and all
patients were in ECOG performance status 1. Eighty
percent of patients were chronic hepatitis B carriers and
all patients had Child A cirrhosis. Among these 10
patients, none of the enrolled patients achieved response
or stable disease. The median time-to-progression was
1.81 months (95 % confidence interval [C.I.], 1.08–
1.74 months) and overall survival was 4.37 months
(95 % C.I., 1.08–11.66 months). Rash (70 %), diarrhea
(50 %) and malaise (40 %) were the most commonly
encountered toxicities. Conclusion The combination of
B+E was well tolerated but had no activity in an
unselected sorafenib-refractory advanced HCC popula-
tion. Condensed abstract The combination of bevacizu-
mab and erlotinib had no clinical activity in sorafenib-
refractory HCC population.
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Introduction
Hepatocellular carcinoma (HCC) is an aggressive cancer
with poor prognosis, representing the third commonest
cause of cancer mortality worldwide [1]. The majority
of HCC patients present with advanced disease not
amenable to loco-regional therapy [2]. In these patients,
systemic treatment with chemotherapy, immunotherapy
or hormonal therapy result in low response rates and no
survival benefit [3].
More recently, increased understanding of the molecular
biology of HCC has facilitated rational development of
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therapeutic targeted agents. Tumor angiogenesis plays a
pivotal role in the development and progression of HCC;
increased expression of vascular endothelial growth factor
(VEGF) is frequently observed in these tumors [4, 5].
Sorafenib, an oral multi-kinase inhibitor, exerts anti-
angiogenic and anti-tumor effects by blocking multiple
growth factor pathways including VEGF receptor
(VEGFR)-1, -2, -3, platelet derived growth factor recep-
tor (PDGFR)-B, RAF, RET and FLT-3[6]. Two pivotal
phase III randomized trials conducted respectively in the
Western [7] and Asian [8] populations have demonstrated
significant survival improvement with single agent sora-
fenib in treating advanced HCC patients, leading to the
approval for use of sorafenib in these patients. On the
other hand, bevacizumab (B), a recombinant humanized
monoclonal antibody that binds VEGF [9], is still under
investigation in HCC. Response rates of 13 % as mono-
therapy [10] and of 11–20 % when combined with che-
motherapy [11–13] were reported in phase II trials.
In addition to angiogenesis, the epidermal growth factor
(EGF) and its receptor (EGFR) also play a crucial role in the
proliferation of HCC [14, 15]. Single agent erlotinib (E), an
EGFR tyrosine kinase inhibitor, achieved modest clinical
benefit in the management of advanced HCC patients in the
phase II setting [16, 17].
These data provide the rationale for evaluating the
combination of B+E in advanced HCC. Two phase II
studies have demonstrated benefit of the combination in
patients who had not received prior anti-VEGF or anti-
EGFR agents [18, 19]. The promising first-line activity
of B+E confirms the importance of VEGF and EGFR
pathways in HCC. On the other hand, there is currently
no standard systemic therapy for patients who progress
after sorafenib. Therefore, in this study, we aimed to
evaluate the efficacy and safety of the combination of
B+E in treating advanced HCC patients who had failed
first-line sorafenib treatment.
Patients and methods
This was an open-label, prospective, single arm pilot study
to investigate the efficacy and safety of B+E combination in
advanced HCC patients who progressed after prior sorafenib
treatment. The protocol was approved by the institutional
ethic committee and written consents were obtained from
the patients before enrollment.
Patient’s eligibility
Advanced HCC patients, who were not suitable for surgery
or various loco-regional therapies at the Queen Mary
Hospital, Hong Kong were enrolled. HCC was diagnosed
either by cyto-histological confirmation or by non-
invasive criteria according to the European Association
for Study of Liver disease (EASL) criteria. Staging was
by both America Joint Committee on Cancer (AJCC) and
Barcelona Clinic Liver Cancer (BCLC) staging. All the
enrolled patients had documented radiological evidence
of disease progression with sorafenib treatment. More-
over, all patients had washout period of about 2 weeks
but not longer than 4 weeks after the last sorafenib
dosing. Other major eligibility criteria included adult
patients aged ≥18 years; patients with Child-Pugh class
A cirrhosis; Eastern Cooperative Oncology Group
(ECOG) performance status 0–1; expected life expectan-
cy of ≥12 weeks and with adequate organ function.
Moreover, the disease must be measurable with at least
1 lesion, which is at least 1 cm in 1 dimension on
computer tomography (CT) or magnetic resonance imaging
(MRI) scan. Major exclusion criteria included prior anti-
VEGF therapy other than sorafenib.
Treatment design and disease evaluation
All patients received B at 10 mg/kg every 2 weeks together
with E at 150 mg daily for a maximum of 6 cycles.
A full history and clinical examination were per-
formed at every clinical visit. Disease assessment was
performed by CT scan every 3 cycles i.e. 6 weeks. MRI
and positron emission tomography (PET) with choline-
acetate as radio-isotope were performed only in case of
diagnostic uncertainty. Response was determined by in-
dependent radiologists and classified according to both
RECIST 1.0 [20] and modified RECIST criteria [21]. All
patients who had received at least one cycle of treatment
were considered evaluable for tumour response and safe-
ty. Toxicities were evaluated according to National Can-
cer Institute (NCI)’s Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0. Patients who had
either complete response (CR), partial response (PR) or
stable disease (SD) were classified as having clinical
benefit (CB) and continued the regimen for another 3
cycles. After six cycles, only patients had CB continued
with erlotinib until progressive disease (PD) or intolera-
ble toxicities.
Safety monitoring
Safety assessments consisted of monitoring and recording
all the adverse events and serious adverse events throughout
the study period. Apart from monitoring of vital signs,
regular collection of urine, hematology and blood chemistry
of the enrolled subjects were performed. All patients who
had received at least one cycle of treatment were considered
evaluable for safety.
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Endpoints
The primary endpoint was CB rate. The secondary end-
points included response rate (RR), serial serum alpha
fetoprotein (AFP) measurements, time to progression
(TTP), overall survival (OS) and safety.
Statistical analysis
The null hypothesis was that B+E would give a CB rate of
no more than 5 %, and the alternative hypothesis was that
the CB was no less than 20 %. Based on Simon’s optimal
two stage design with 5 % maximal tolerable false positive
rate and 20 % maximal tolerable false negative rate, 10
patients would be enrolled at stage one. If no patient shows
any CB, the study would be terminated, with the conclusion
that the CB rate was ≤5 %. If one or more patients derived
CB, then up to 29 patients in total would be enrolled. If
more than three patients had CB, we then rejected the null
hypothesis and considered B+E sufficiently promising to
warrant further study.
Survival analysis was computed by the Kaplan-Meier
method. TTP was calculated from the date of commence-
ment of study drugs to the date of documented progression
or death. OS was calculated from the date of commence-
ment of study drugs to the date of death or last follow-up.
The analysis was performed on intent-to-treat basis. All
statistical analyses were performed by R version 2.13.2 for
Windows.
Results
Patient demographics
Between August, 2007 and May, 2008, 10 patients were
recruited at first stage. They all received B at 10 mg/kg
every 2 weeks together with E at 150 mg for the treatment
of advanced HCC after sorafenib failure. Table 1 shows the
demographic data of these patients. The median age was
47 years (range, 28–61 years) and the majority was male
patients (70 %). All the enrolled patients had ECOG perfor-
mance status 1. Eight (80 %) patients were chronic hepatitis
B carriers and none of them were chronic hepatitis C car-
riers. Notably, all recruited patients had underlying Child
cirrhosis. All patients had advanced disease at the time of
enrollment with half of the patients had elevated alpha-fetal
protein (AFP) level. Nearly all patients were in BCLC stage
C disease except one. The commonest site of metastases was
lung (60 %) and main portal vein invasion was present in
three patients (30 %). Four patients had received prior liver
resection for HCC but none of the patients had undergone
liver transplantation. Three enrolled patients had received
Table 1 Demographic data of the enrolled patients in the study
Characteristics
Age (years)
Median 47
Range 28–61
Sex
Male 7 (70 %)
Female 3 (30 %)
ECOG
0 0 (0 %)
1 10 (100 %)
Hepatitis Serology
Hep Bs Ag positive 8 (80 %)
Anti-HCVAb positive (n08) 0 (0 %)
Child-Pugh Status
A 10 (100 %)
B 0 (0 %)
C 0 (0 %)
Alpha-fetal Protein (AFP)
≤400 5 (50 %)
>400 5 (50 %)
Disease Stage at the Time of Study Entry
AJCC Staging
I 0 (0 %)
II 0 (0 %)
IIIA 3 (30 %)
IIIB 0 (0 %)
IIIC 0 (0 %)
IV 7 (70 %)
BCLC
A 0 (0 %)
B 1 (10 %)
C 9 (90 %)
D 0 (0 %)
Distant Metastases
Lung 6 (60 %)
Bone 2 (20 %)
Adrenal 0 (0 %)
Spleen 1 (10 %)
Brain 1 (10 %)
Invasion of Major Vessels
Main portal vein invasion 3 (30 %)
Hepatic vein invasion 0 (0 %)
Inferior vena cava invasion 2 (20 %)
Prior Treatment
Surgical Treatment
Liver resection 4 (40 %)
Liver transplantation 0 (0 %)
Local Ablative Procedures
TACE 2 (20 %)
RFA 1 (10 %)
2386 Invest New Drugs (2012) 30:2384–2390
prior palliative radiotherapy for the treatment of advanced
HCC. All the enrolled patients had received single agent
sorafenib as the first-line systemic treatment for advanced
HCC. The median duration of prior sorafenib was
2.76 months (range, 2.12–6.18 months). None of these ten
patients had demonstrated major treatment response to prior
sorafenib treatment. They were all confirmed to have devel-
oped radiological progression with sorafenib treatment.
Treatment efficacy and survival analysis
Table 2 summarizes the efficacy and the survival analysis of
the enrolled patients. Two patients only received 2 cycles of
B+E and died rapidly due to disease progression without
formal radiological assessment for treatment response.
The overall response rate was 0 % with no CR or PR
observed in the enrolled cohort according to either RECIST
1.0 or modified RECIST criteria. Moreover, none of the
enrolled patients had demonstrated SD. There was no sig-
nificant drop in AFP level (.20 %) compared to the baseline
in all the enrolled patients. The overall CB rate was 0 %.
The median TTP was 1.81 months (95 % confidence inter-
val [C.I.], 1.08–1.74 months) and OS was 4.37 months
(95 % C.I., 1.08–11.66 months) (Figs. 1, 2). Thus, the
primary endpoint of the study was not met and it was halted
in the first stage according to the pre-set statistical criteria,
with a conclusion that the CB rate to the B+E combination
for sorafenib refractory patients was no more than 5 %.
Treatment-related toxicities
Table 3 shows the details of treatment-related toxicities in
the enrolled patients. Grade 3 or 4 non-hematological toxic-
ities were reported in 20 % of the enrolled patients. Regarding
the bleeding risk, only one enrolled patient experienced grade
3 bleeding from the upper gastrointestinal tract. Overall, two
patients had transient treatment interruption due to grade 3
non-haematological toxicities and none of the enrolled
patients died of treatment-related complications.
Discussion
In the past few decades, there has been a step forward in the
treatment of advanced HCC. Sorafenib has demonstrated
modest activity in improving the clinical outcome of this
lethal disease. To date, it is the only approved targeted
agent for this indication. On the other hand, the absolute
Table 1 (continued)
Characteristics
Systemic Therapy
Sorafenib 10 (100 %)
Doxorubicin 1(10 %)
Radiotherapy 3 (30 %)
Hep Bs Ag Hepatitis B surface antigen; Anti-HCV Ab Anti-hepatitis C
antibody; TACE Transarterial chemo-embolization; RFA Radiofre-
quency ablation; AJCC America Joint Committee on Cancer; BCLC
Barcelona Clinic Liver Cancer; TACE Transarterial chemoembolisa-
tion; RFA Radiofrequency ablation
Table 2 Treatment efficacy and survival analysis
Duration of Prior Sorafenib Treatment (months)
Median (range) 2.76 (2.12–6.18)
Number of B+E Treatment Cycles
1 0 (0 %)
2 2 (20 %)
3 8 (80 %)
Overall Survival (months)
Median (95 % C.I.) 4.37 (1.08, 11.66)
Progression-free Survival (months)
Median (95 % C.I.) 1.51 (1.08, 1.74)
Fig. 1 Kaplan-Meier curve of time to progression of the enrolled patients
Fig. 2 Kaplan-Meier curve of overall survival of the enrolled patients
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magnitude of clinical benefit in terms of OS associated
with sorafenib was only 2–3 months [7, 8]. Furthermore,
all patients on sorafenib eventually progress on the treat-
ment. The growing sorafenib-refractory patient popula-
tion is therefore an important clinical problem and the
development of second-line treatment is urgently needed
in the HCC community. The current study explores the
role of further biological pathway inhibition after sorafe-
nib failure; it is the first reported in the literature evaluating
the combination of B and E in patients who had received prior
sorafenib treatment. The results of the present study showed
that B+E was well tolerated in advanced HCC patients pre-
viously treated by sorafenib and/or other therapies. However,
it did not demonstrate any signal of activity in using B+E
combination in treating advanced HCC progressed after sor-
afenib failure.
Thus far in the literature, there are only two published
studies in evaluating the efficacy of B+E in treating ad-
vanced HCC patients and all these studies were tested in the
patients naïve to anti-VEGF therapies. An impressive RR of
25 %, median progression free survival (PFS) of 9 months
and OS of 15.65 months were reported in a single institute
phase II trial which included 40 advanced HCC patients
[18]. This trial had excluded patients who had prior anti-
VEGF or anti-EGFR agents, although 20 % of the enrolled
patients had been treated with one line of systemic chemo-
therapy. Notably, with longer follow-up period and recruit-
ment of more patients, the overall RR (28 %) and CB rate
(90 %) were maintained. Nevertheless, the PFS (7.9 months)
and OS (12.8 months) were not as impressive as the results
shown in the initial report [22]. On the other hand, Philip et
al. recently reported the results of a multi-institutional phase
2 study with similar design to the aforesaid study; only one
out of 27 patients had PR while 11 % had SD, with median
PFS of 3 months and OS of 9.5 months [19]. In distinct
contrast to the study performed by Thomas et al. [18], the
results of the phase 2 study performed by Philip et al. did not
support the activity in using B+E combination in treating
advanced HCC patients who were naïve to anti-VEGF ther-
apy. In fact, the combination of B+E with different dosing
schedules of B has also been tested in various solid malig-
nancies with poor results. Ko et al. had performed the phase
II study in testing the use of B+E in the treatment of
gemcitabine-refractory advanced pancreatic cancer with
disappointing results [23]. Dickler et al. also showed that
the combination of B+E had very limited activity in
treating unselected patients with metastatic breast cancer
[24]. Similarly, the combination has minimal clinical
activity in patients with advanced upper gastrointestinal
cancers [25] and recurrent advanced squamous cell carcinoma
of the head and neck [26]. All the aforementioned studies
consistently demonstrated that although B+E was a fairly
well tolerated regime, it had minimal clinical activity in
various solid malignancies.
The mechanisms of resistance to sorafenib in HCC are
still poorly understood. Proposed mechanisms of sorafenib
resistance include enhanced alternative pro-angiogenic sig-
naling, which may result either from an upregulation of
alternative pathways or from the pre-existence of multiple
redundant signals [27]. Importantly, increased capabilities
for proliferation and invasion without angiogenesis may
also be observed in resistance to anti-VEGF therapies [27].
Thus, continued anti-angiogenic therapy with B, combined
with E inhibiting an additional essential tumor growth path-
way in HCC, and may potentially circumvent sorafenib
resistance. Nonetheless, our results showed that the combi-
nation has no activity after sorafenib failure. The negative
results may be explained by few reasons. First, tumour
dependence on pro-angiogenic factors may be altered after
sorafenib treatment [28]. The vascular remodeling due to
pericytic over-coverage renders the neovasculature less re-
sponsive to VEGF for growth dependence effectively circum-
venting a blocked signaling pathway with greater dependence
on other alternate mechanisms [29]. Second, it has been
shown that the inhibition of VEGF receptors may result in
an increased propensity for metastatic dissemination as the
hypoxic microenvironment associated with the sorafenib
use selects for highly aggressive, invasive tumor cells
Table 3 Summary of toxicities associated with Bevacizumab and
Erlotinib combination
Toxicity Any
grade
Grade 1–2
(%)
Grade 3
(%)
Grade 4
(%)
Non-haematological
Diarrhea 5 (50 %) 4 (40 %) 1 (10 %) 0 (0 %)
Malaise 4 (40 %) 4 (40 %) 0 (0 %) 0 (0 %)
HFSR 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Alopecia 2 (20 %) 2 (20 %) 0 (0 %) 0 (0 %)
Rash 7 (70 %) 6 (60 %) 1 (10 %) 0 (0 %)
Abdominal pain 2 (20 %) 2 (20 %) 0 (0 %) 0 (0 %)
Hypertension 1 (10 %) 1 (10 %) 0 (0 %) 0 (0 %)
Nausea 2 (20 %) 2 (20 %) 0 (0 %) 0 (0 %)
Mucositis 1 (10 %) 0 (0 %) 1 (10 %) 0 (0 %)
Constipation 1 (10 %) 1 (10 %) 0 (0 %) 0 (0 %)
Vomiting 1 (10 %) 0 (0 %) 1 (10 %) 0 (0 %)
Haematological
Thrombocytopenia 2 (20 %) 2 (20 %) 0 (0 %) 0 (0 %)
Neutropenia 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Leukocytopenia 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Anemia 1 (10 %) 1 (10 %) 0 (0 %) 0 (0 %)
Biochemical
Hyperbilirubinemia 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
ALT 2 (20 %) 1 (10 %) 1 (10 %) 0 (0 %)
AST 2 (20 %) 1 (10 %) 1 (10 %) 0 (0 %)
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[30]. Therefore, the increase in the biological aggressive-
ness of the tumor following sorafenib resistance may
account for the poor response to subsequent systemic
therapy. Third, other factors including fibroblast growth
factors (FGFs), insulin like growth factors (IGFs), angio-
poietins, and tumor-stromal interaction may contribute to
sorafenib resistance [27]. These may enable tumors to
evade inhibition by B+E. Last but not least, vascular
remodeling may play a significant role in the resistance
to B+E. Tumors that grow during sorafenib treatment
developed as viable clusters surrounding strikingly
remodeled vessels. These vessels display significant
increases in active proliferation of vascular mural cells,
expression of platelet-derived growth factor-B and eph-
rinB2. Thus, enhanced vascular stability accounts for the
poor response to B+E combination [31].
There are important limitations in the current study
needed to be addressed. Firstly, none within our patient
cohort had derived major tumor response while on sor-
afenib, suggesting that these patients might be intrinsi-
cally resistant to any anti-angiogenic strategies. Whether
B+E is active in patients with initial response but ac-
quired resistance to sorafenib cannot be concluded from
the current study. Secondly, the relative small number of
patients recruited from a single institute in the present
study is noteworthy. Thus, our present findings should be
regarded as exploratory rather than confirmatory. Last but
not least, the safety profile of the combination reported
from this study is based on a very limited number of
enrolled patients, thus these data should be regarded as
preliminary and interpreted cautiously. There are few
ongoing trials both in US and Asia for investigating the
potential benefits in employing B+E in treating advanced
HCC patients. In particular, a single arm phase II trial is
currently conducted in MD Anderson Cancer Centre in
evaluating the role of B+E as a second-line therapy in
patients who have progressed after first-line sorafenib
treatment [32]. The final results of this study will be
eagerly awaited to provide more data about the benefits
of B+E in advanced HCC patients progressed after sor-
afenib treatment. More importantly, the development of
biomarkers to select patients likely to benefit from tar-
geted therapy cannot be over-emphasized. In a recent
study, high VEGF expression was correlated to longer
OS and high VEGFR-2 expression to shorter PFS in
upper GI cancers treated with B+E, while EGFR expres-
sion and KRAS mutation status were not predictive [33].
Prospectively designed clinical trials with rigorous tissue
sampling are desperately needed.
In conclusion, the combination of B+E is inactive in an
unselected population of sorafenib-refractory advanced
HCC patients. Further evaluation of this combination in
biomarker-selected patients may be warranted.
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